RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.
Read original at benzingaStocks · News reference
Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60%
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up to $2.3 billion.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 21, 2026, 8:07 PM
- Checked
- Jul 21, 2026, 8:07 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $34 price target.
Read original at benzingaNurix Therapeutics Earns $10M Milestone Payment Following Initiation Of Sanofi's Phase 1 Clinical Study Of SAR448272/NX-3911
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has
Read original at benzingaNurix Therapeutics Enrolls First Patient In Registrational Phase 3 DAYBreak CLL-306 Trial Of Bexobrutideg For Relapsed/Refractory CLL/SLL
Read original at benzinga